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The  molecular  basis  of immunoglobulin  idiotypes (1)  has  been  pursued  in 
several well-defined antibody systems (2-7).  The accumulated results have sug- 
gested  that  the  hypervariable  regions  (complementarity-determining  regions, 
CDR) 1 of the  light  and  heavy  polypeptide  chains  usually  contribute  to  the 
formation  of idiotypic determinants.  In  the  extensively analyzed  murine  anti- 
dextran  model,  one  private  idiotype  and  one  public  idiotype  (cross-reactive 
idiotypes, CRI) were assigned, respectively to the third and the second hypervar- 
iable regions of the heavy chain (6).  In most other cases, idiotypic determinants 
have not  been associated definitively with  a  specific amino  acid  sequence (2). 
The latter result is not surprising, considering that antiidiotype antibodies elicited 
by  immunization  with  intact  immunoglobulin  often  recognize  determinants 
dependent upon a particular quaternary interaction of the light and heavy chains 
(2). 
Using  carefully  absorbed  rabbit  antisera,  Kunkel  and  colleagues  (8)  first 
described the unusual  existence of two major CRI (Wa and Po) among human 
monoclonal  IgM anti-IgG  autoantibodies (rheumatoid  factors,  RF) from  unre- 
lated individuals with cryogiobulinemia. The larger Wa group includes ~60% of 
monoional IgM-RF (8, 9).  Amino acid sequence analysis of the variable regions 
of two Wa-CRI positive IgM-RF (Sie and Wol) has revealed a marked homology 
between the  kappa  light  chains,  but  not  the  heavy chains  (10).  However, the 
precise chemical nature of the Wa-CRI has remained unclear. 
To clarify these issues, we generated a murine monoclonal antibody (mAb 17- 
109) that recognized a CRI shared by the Wa-CRI positive IgM-RF Sie and Glo 
but not by the  Wa-CRI  negative  IgM-RF  Lay and  Pom (1 1).  Although  made 
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against the intact IgM-RF Sie protein, the mAb 17-109 also reacted with isolated 
kappa  chains  from  Wa-CRI  positive  IgM-RFs.  A  comparison  of the  reported 
amino  acid  sequences  of the  kappa  chains  of the  Wa-CRI  positive  IgM-RF 
indicated  that  among  the  three  CDR,  only  the  second  CDR  was  identical 
(reference 10 and Table I). 
Antibodies against synthetic peptides have been able to identify with precision 
predefined  antigenic  determinants  in  intact  proteins  (12-14).  Recently,  we 
prepared  an  antiidiotype  against  a  "private,"  or  individually  specific idiotypic 
determinant  on  IgM-RF Sie,  by immunization  with  a  synthetic peptide  corre- 
sponding  to  the  third  CDR of the  heavy chain  (15).  It  seems possible that  a 
similar strategy would enable us to determine the relationship between the CDR 
shared in common by human  IgM-RF, and the CRI-Wa.  The current  commu- 
nication demonstrates the success of this approach in delineating the structural 
basis of a CRI on human autoantibodies. 
Materials and Methods 
Preparation of the Synthetic Peptide.  A peptide, designated PSL2, was synthesized  that 
corresponded to amino acid residues 49-61 (second CDR and its neighbors, Table I; 16) 
in the light chain of the monoclonal IgM-RF Sie, according to the sequence reported by 
Andrews and Capra (10). It was composed of tyr-gly-ala-ser-ser-arg-ala-thr-gly-ile-pro-asp- 
arg.  An additional  cys was added  to the  C-terminal  end  of the sequence to facilitate 
coupling to the protein carrier (15). 
The PSL2 was prepared by the solid-phase method (17), slightly modified as previously 
described (15, 18). Briefly, N-tert-butoxy-carbonyl-tyrosine  (BOC-tyr)-resin was used along 
with the following side chain protecting groups: (O-bromo-benzyoxycarbonyl)  for tyrosine; 
O-benzyl for threonine, serine,  and aspartic acid; S-methoxybenzyl  for cysteine; tosyl for 
arginine.  All couplings used a 10-fold excess of protected amino acid plus dicylohexylcar- 
bodiimide.  The reactions were 99%  complete by the picric  acid test.  At the end,  the 
peptide polymer was treated with anhydrous hydrogen fluoride. The cleaved peptide was 
extracted with anhydrous ether. The amino acid analysis of the peptide was within 5% of 
theory. 
The synthesis of the control PSH3 (corresponding to the third CDR of the H chain of 
the IgM-RF Sie) has been described previously (15). It was composed of glu-trp-lys-gly- 
gln-val-asn-val-asn-pro-phe-asp-tyr-gly-gly-cys. 
TABLE  I 
Amino Acid Sequences of the Kappa Chains of  Human Monoclonal IgM-RF Paraproteins in the 
Second CDR and Adjacent Framework Region 
IgM-RF  CRI*  Region*:  FR-2  CDR-2  FR-3 
Residue*:  49  50  51  52  53  54  55  56  57  58  59  60  61 
1.  Sie  I  Wa 
2.  Woll  Wa 
3.  Pom  I  Po 
4.  Lay  I  Po 
5.  Got  s  NA 
6.  Neu  1  NA 
7.  Pay  I  NA 
8.  Gar  I  NA 
Tyr  Gly  Ala  Ser  Ser  Arg  Ala  Thr  Gly  lie  Pro  Asp  Arg 
m 
Thr  Ala -- 
Thr  Glu  Ala  ---  Val  --  Ser 
* The region and the residue number were assigned by Kabat (16). FR, framework  region. 
* The cross-reactive  idiotypes (CRI) were determined by Kunkel et al. (8). NA, idiotype not assigned. 
! Amino acid sequences  were reported by Andrews and Capra (10). 
I Amino acid sequences  were reported by Klapper and Capra (5). 
I Amino acid sequences  were reported by Ledford et al. (21). 1504  SYNTHETIC PEPTIDE-INDUCED  ANTI-CROSS-REACTIVE  IDIOTYPE 
Immunization of Animals.  The synthetic peptide PSL2 was conjugated via its terminal 
cysteine to keyhole limpet hemocyanin (KLH) with M-maleimidobenzoyl N-hydroxysuc- 
cinamide  ester,  as  described  previously (15,  19).  Each  of three  rabbits  was  injected 
subcutaneously with 2.5 mg of the conjugate, emulsified in complete Freund's adjuvant. 
The injection was repeated two months later. 3 wk after the second immunization, the 
rabbits were  boosted again  with  2.5  mg glutaraidehyde cross-linked peptide PSL2 in 
incomplete  Freund's  adjuvant.  The  latter  reagent  was  prepared  by  the  addition  of 
glutaraldehyde (final concentration 0.25% vol/vol) to a  5 mg]ml solution of peptide in 
isotonic phosphate-buffered saline (PBS), followed by 1 h incubation at room temperature, 
and immediate suspension in adjuvant. Thereafter, the rabbits were bled, and the sera 
was stored at 20°C until analyzed. 
Purification of Proteins.  Plasma, purified proteins, or purified light chains (of IgM-RF 
Got) from patients with monoclonal IgM cryoglobulins were kindly donated by Drs. J. D. 
Capra,  G.  Abraham,  F.  Goni,  B.  Frangione, J. Johnson,  and  H.  Metzger.  The  IgM 
cryoglobulins were purified by repeated precipitation at 4 °  C, followed by chromatography 
on Sephadex G-200 or Ulltrogel AcA 22 in 0.2 M sodium acetate, pH 3.5. IgM and IgG 
peaks were identified by immunodiffusion. The appropriate fractions were pooled and 
stored at -20 °C. Pooled human IgG was prepared from Cohn fraction II (Sigma Chemical 
Co., St. Louis, MO) by DEAE cellulose chromatography in 0.01 M sodium phosphate, pH 
8.0. Pooled polyclonal human IgM was purchased from Calbiochem-Behring Corp. (La 
Jolla, CA). 
The heavy and light chains of the IgM-RF proteins Sie and GIo were separated on a 
Sephadex G-100 column with 1 M acetic acid, or a TSK-250 column (Bio-Rad Laborato- 
ries, Richmond, CA) with  1 M propanoic acid, after complete reduction and alkylation 
(20). The polypeptides were stored frozen at 1 mg/ml. Using a radioimmunoassay specific 
for IgM heavy chains or kappa chains, we estimated that the heavy chains contained not 
more than  5% light chains,  while the light chains contained not more than  2% heavy 
chains. 
Enzyme-linked Immunosorbent Assay (ELISA).  Either synthetic peptides (100 or 2 ug/ml), 
various purified monoclonai IgM-RF (I0 or 2 #g]ml), isolated light chains from the IgM- 
RF proteins (10 or 2 ~g/ml), affinity purified anti-peptide antibody (8 ~g/ml), or antibody- 
depleted rabbit IgG (8 #g/ml) were each dissolved in 0.1 M borate, 0.2 M NaCi, pH 8.2 
(BBS), and were added to plastic microtiter plates (Costar #3590) at t 00 ul]well. After an 
overnight incubation at 4°C,  the plates were washed twice with BBS contianing 0.5% 
Tween-20 (Sigma #P-1379, BBS/Tween-20) and were quenched with BBS containing 1% 
bovine serum  albumin  (BSA)  for  1 h  at room temperature.  Then,  100 #1 of various 
samples diluted in BBS containing 0.5% BSA were distributed to duplicate wells. After 
incubation for 3  h,  the plates were washed with  BBS/Tween-20. Aliquots of a  1:500 
dilution in PBS of human IgG-adsorbed, alkaline phosphatase-labeled, goat anti-rabbit 
IgG (Kirkegaard and Perry, Gaithersburg, MD), were dispensed to the wells. The plates 
were incubated for 1 h at room temperature. After washing, p-nitrophenyl phosphate (1 
mg/ml) in  0.05  M  sodium carbonate, pH  9.8  was  added  to each well.  After  1-16  h 
incubation, the absorption at A405 was measured. Inhibition of the anti-peptide antibody 
binding to plates coated with IgM-RF or the isolated light chains of IgM-RF was assessed 
similarly, except that the anti-PSL2 antiserum (at 1:100 dilution) was first mixed with an 
equal volume of the different inhibitors. 
To assess the binding of liquid phase IgM-RF Sie to coated anti-PSL2 antibody, bovine 
intestine alkaline  phosphatase  (Sigma  Chemical  Co.) was  first coupled to  IgM-RF  Sie 
according to the manufacturer's instructions.  Then,  the  standard  ELISA method was 
modified as follows.  75-~tl aliquots of the PSL2 peptide, the PSH3 control peptide, or 
buffer alone were added  to wells  precoated with  anti-peptide antibodies or antibody- 
depleted IgG. After  1 h  incubation at room temperature, 75 t~l of enzyme-conjugated 
IgM-RF Sie was distributed to the wells. The plate was incubated 1.5 h at room temper- 
ature, and enzyme activity was measured. 
Adsorption and Elution of the IgM-RF Sie-binding Activity.  The globulins (100 mg) from 
8 ml of anti-peptide antiserum were precipitated with 33% saturated ammonium sulfate, CHEN  ET  AL.  1505 
and redissolved in  10  ml of BBS.  The solution  was passed through  a  BSA-column to 
remove nonspecific  binding  activity,  and  then  was  recirculated  over a  PSL2-coupled 
Sepharose 4B affinity column (ca.  1.6 mg/ml gel x  3 ml), that had been prepared with 
cyanogen bromide activated Sepharose-4B (Sigma Chemical Co.). After removal of non- 
bound material with BBS, the anti-peptide antibody was eluted with 0.1  M glycine HCI, 
pH 2.5, and then was dialyzed against BBS. 
Results 
Induction of Anti-RF Antibody with the PSL2 Peptide.  After receiving two sub- 
cutaneous injections of the  PSL2 peptide conjugated to KLH and one injection 
of glutaraldehyde  cross-linked  peptide,  the  three  rabbits  were  bled,  and  their 
sera were analyzed for anti-peptide antibody activity by the  ELISA method. As 
shown in Table II, all three antisera contained high titers ofanti-PSL2 antibodies. 
Notably,  the  three  antisera also reacted  with plates coated with intact  IgM-RF 
Sie.  Under  the  same conditions  pooled sera from normal  rabbits did not bind 
significantly  to  plates coated  with  PSL2  or  IgM-RF  Sie.  In addition,  the  anti- 
PSL2  immune  sera  did  not  react  with  plates  coated  with  the  control  peptide 
PSH3, or the Wa-CRI negative IgM-RF Lay. 
Association  of Anti-RF Antibody Activity  with the PSL2 Peptide.  Three  different 
experiments  showed  that  the  anti-RF  antibody  induced  by  the  PSL2  peptide 
recognized a specific PSL2 peptide-determined antigen. First, as shown in Table 
II, experiment 2, the antisera reacted with the isolated light chain, but not the 
heavy chain,  of the  IgM-RF Sie.  Second, the binding of the anti-PSL2 antibody 
to both intact  IgM-RF Sie and to the isolated light chain of Sie (Table III) was 
completely inhibited  by the  free  PSL2  peptide,  but  not  by the  control  PSH3 
TABLE  II 
Induction of Anti-RF Antibodies with the PSL2 Peptide* 
Rabbit 
Experiment  antiserum 
Antigen: (A4o5 X l0  s) 
Peptide  IgM-RF  IgM-RF-Sie 
Light  Heavy 
PSL2  PSH3  Sie  Lay  chains  chains 
1.* 
2.1 
Normal  23  25  35  28  --**  16 
Anti-PSL2 (1)  t  1,036  9  136  22  m  9 
Anti-PSL2 (2)  948  24  92  19  --  13 
Anti-IgM  15  38  1,602  1,453  --  962 
Normal  6  7  9  7  14  14 
Anti-PSL2 (1)  430  14  64  7  228  14 
Anti-PSL2 (3)  489  18  110  17  420  23 
Anti-IgM  0  1  637  441  378  525 
Anti-PSH3  ~  6  668  259  0  30  510 
* Anti-peptide antisera were assayed at 1:1,000 dilution, and anti-IgM antisera at 1:10,000 dilution. 
Bound antibodies were detected  with alkaline phosphatase-conjugated  goat anti-rabbit IgG and 
substrate. The numbers represent A405 measured after 1 h incubation at room temperature. 
* Antigens were coated at either 100 #g/ml (peptides) or 10 ~g/ml (IgM-RF and isolated chains). 
| Antigens were coated at 2/zg/mi. 
! The numbers in parentheses designate the three rabbit anti-PSL9 antisera. 
Antiserum from a rabbit immunized with the control peptide PSH3 (15). 
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TABLE  III 
Inhibition of Anti-PSL2 Binding to IgM-RF by the Free PSL2 Peptide* 
IgM-RF 
Percent inhibition* 
peptide: 
PSL2  PSH3 
50  500  5,000  50  500  5,000 
ng/,nt 
Sie  29  85  100  0  0  0 
Sie kappa chains  93  96  97  5  5  5 
Glo kappa chains  69  100  100  10  5  4 
Gar  70  81  80  7  0  0 
Got  92  96  99  5  14  4 
Neu  87  96  98  1  0  3 
Pay  89  92  90  9  6  0 
Got-L  84  93  95  2  6  1 
* Increasing amounts of peptide inhibitors were added to anti-PSL2 antiserum 1:100 
in BBS before distribution to wells previously coated with the indicated IgM-RF or 
the isolated light chains of IgM-RF. The A405 was measured 1 h after the addition of 
substrate to the wells. 
* Percent inhibition =  100 -  100  ×  (Anti-PSL2 antiserum with inhibitors -  Normal 
rabbit serum)/(Anti-PSL2 antiserum -  Normal rabbit serum). 
TABLE  IV 
Adsorption and Elution of the Anti-RF Activity from a PSL2-Coupled Affinity 
Column 
Antibody 
Antigen coated (A4o5 X lO  s) 
BSA  Peptide  IgM-RF Sie 
Original, 10 #g/ml  24  1,319  303 
BSA adsorbed, 10 ug/ml  0  1,214  250 
BSA and PSL2 adsorbed, 10 #g/ml  0  38  25 
PSL2 eluate 10 t~g/ml  12  1,859  730 
PSL2 eluate (1 ~g/ml)  0  1,616  375 
An IgG fraction (100 rag) of anti-PSL2 antiserum in 10 ml BBS was first adsorbed 
with a 3-ml BSA-agarose column (5 mg/ml gel), and then was loaded onto a 3- 
ml PSL2-coupled column (1.6  mg/mi gel).  After 15  min incubation at room 
temperature, the effluent was collected. After washing with  BBS, the bound 
material was eluted with 0.1 M glycine-HCl, pH 2.5 and was dialyzed into BBS. 
The ELISA was done as described in Table II. 
peptide. Third,  the anti-Sie antibody activity was adsorbed  by, and eluted from 
a  PSL2-coupled Sepharose affinity column (Table IV). 
Defining a CRI on Human IgM-RF with Anti-PSL2 Antibodies.  Among  monoclo- 
nal IgM-RF, affinity-purified anti-PSL2 antibody  reacted strongly with  Sie and 
Glo, weakly with  Pom, and not at all with  Lay (Table V,  Experiments  1 and  2). 
Under  the  same  conditions,  the  anti-PSL2  antibody  did not  react  significantly 
with pooled human  IgM and IgG. Furthermore,  the anti-PSL2 antibody reacted 
with the isolated kappa chains of IgM-RF Glo. The  binding was inhibited by the 
free PSL2 peptide, but not by the control PSH3  peptide (Table III). 
Subsequent  to  the  completion  of  the  above  experiments,  Ledford  and  co- CHEN  ET  AL. 
TABLE V 
Reactivity of Affinity-purified Anti-PSL2 Antibody with Human Monoclonal IgM-RF 
1507 
Experiment  Antigen coated ! 
A40~ x  l0  b* Sample 
Anti-PSL2  Anti-PSL2  Specific  Anti_igM  b 
enriched  depleted  binding 
1. 
2. 
3. 
4. 
Sie  1,388  399  989  ND 
Pom  549  349  200  ND 
Lay  50  16  34  ND 
Sie  1,545  144  1,401  ND 
Glo  >1,999  686  >1,313  ND 
Lay  57  31  26  ND 
Pooled IgM  61  35  26  ND 
Pooled IgG  60  27  33  ND 
Sie  456  57  399  912 
Glo  603  126  477  695 
Lay  19  13  6  781 
Pooled IgM  33  15  18  624 
Pooled IgG  26  8  18  237 
Got  505  3  502  25 
Neu  1,262  4  1,258  171 
Pay  567  1  566  56 
Sie  1,861  177  1,684  ND 
Neu  564  22  542  ND 
Gar  508  21  487  ND 
*  A405 was measured after overnight incubation at room temperature. 
* Anti-PSL2-enriched  and -depleted IgG are the eluate and the peptide adsorbed fractions described 
in Table IV. Each was used at 1 #g/ml. Anti-IgM antiserum was diluted  1:10,000. ND, not done. 
! Specific binding = A405 of enriched anti-PSL2 antibody -  A405 of antibody-depleted IgG. 
! Antigens were coated at 2 #g/ml. 
workers  (21)  reported  several  new  sequences  of  monoclonal  IgM-RF  kappa 
chains. These investigators kindly made available to us some of the proteins.  As 
shown in Table I, the amino acid sequences of the kappa chains of the Got, Neu, 
Pay, and Gar proteins are the same as Sie in the PSL2-associated region.  Table 
V  (Experiments 3  and 4) shows that each of the four different IgM-RF, as well 
as the isolated light chain of IgM-RF Got, was identified by affinity-purified anti- 
PSL2  antibody.  Once  again  the  binding  was  inhibited  specifically by the  free 
PSL2 peptide (Table III). 
Binding of lgM-RF in Solution  to Anti-PSL2 Antibody.  Conceivably, the coating 
of IgM-RF onto plastic wells might denature the immunoglobulin sufficiently to 
allow exposure of a  CDR-2 associated idiotypic antigen  that  was not  expressed 
by intact IgM, or by free kappa chains. To explore this possibility, we tested the 
binding  of IgM-RF Sie  in  solution  to  affinity-purified  anti-PSL2  antibody.  As 
shown  in  Fig.  1,  alkaline  phosphatase-labeled  IgM-RF  Sie  in  solution  bound 
directly to anti-PSL2 antibody-coated plates.  The reaction  was inhibited by the 
free PSL2 peptide. 1508  SYNTHETIC  PEPTIDE-INDUCED  ANTI-CROSS-REACTIVE IDIOTYPE 
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FIGURE  1.  Inhibition by free peptide of IgM-RF Sie binding to anti-peptide coated plates. 
Increasing amounts of peptides PSL2 (O) or PSH3 (A) were added  to wells precoated with 
affinity-purified anti-PSL2  antibody.  After  1  h  incubation  at  room  temperature,  enzyme- 
labeled IgM-RF Sie (10/~g/ml) was added  to each well. 90 min later, the plate was washed, 
and A40~'~vas measured  1 h after the addition of substrate to the wells. 
Discussion 
The  present  experiments describe  the antiidiotypic properties  of antibody 
against a defined hypervariable region peptide shared by many human IgM-RF 
autoantibodies. The antibody was generated by immunization of rabbits  with 
synthetic peptide (PSL2) corresponding to the second CDR and adjacent residues 
on the kappa chain of the monoclonal human IgM-RF Sie. The antibody reacted 
efficiently with (a) the intact  IgM-RF Sie protein,  (b) the IgM-RF Glo, which 
shares a kappa chain associated CRI with IgM-RF Sie (11), and (c) four recently 
described monoclonal IgM-RF paraproteins (Neu, Gar,  Pay, and Got),  whose 
kappa chains include the PSL2 sequence (21).  In addition, the antibody cross- 
reacted weakly with IgM-RF Pom, whose kappa chains differ from IgM-RF Sie 
by two residues in the PSL2  region. The antibody did not react with pooled 
human IgM and IgG, nor with IgM-RF Lay, whose kappa chains differ from 
IgM-RF Sie by  five amino acid residues in  the  PSL2  region. The anti-PSL2 
antibody recognized the isolated kappa chains of the IgM-RF paraproteins Sie, 
Glo,  and  Got,  but  did not  bind  the  isolated Sie  and  Glo  heavy chains.  The 
binding of the antiserum to all reactive IgM-RF and to the light chains of Sie, 
Glo, and Got, was completely inhibited by the free PSL2 peptide, but not by a 
control  peptide,  PSH3.  Collectively,  these  results  strongly  suggest  that  the 
synthetic PSL2 peptide induced an antiidiotype against a  CRI associated with 
the kappa light chains of human IgM-RF autoantibodies. The molecular basis of 
this CRI is delineated by the PSL2 amino acid sequence. 
The  classic  studies  of Kunkel and  co-workers  (8)  originally demonstrated 
similarities in the light chains of IgM-RF paraproteins showing cross-idiotypic 
specificities.  These investigators discovered that for the majority of IgM-RF, the 
light chains were kappa in type, kappa III in subgroup, and kappa IIIb in sub- 
subgroup  (9). They  further  suggested  that  perhaps  a  kappa  IIIb'  sub-sub- 
subgroup accounted for the observed cross-idiotypy. The present association of 
a CRI on human IgM-RF paraproteins with a predefined sequence represented CHEN  ET  AL.  1509 
by  the  PSL2  peptide  is  a  logical outcome of these  earlier predictions.  The 
delineation of a specific peptide-defined antigen in the variable regions of the 
light chains of human IgM-RF coalesces the former distinction between idiotype, 
variable region allotype and sub-sub-subgroup. An important objective of future 
studies will be to determine the incidence of the same CDR sequence among RF 
and non-RF kappa chains in families and populations. Eventually, one must also 
ascertain whether or not the related DNA sequence is represented in the germ 
line kappa V-region pool of patients with idiotype-positive proteins. The availa- 
bility of oligonucleotide probes corresponding to the PSL2 peptide would facil- 
itate such studies. 
Family studies have shown that the individually specific idiotypes on IgM-RF 
~utoantibodies may be inherited (22). However, the exact genetic interpretation 
ff the serological data has remained unclear, because the full expression of the 
RF idiotype depended on both the light chains and heavy chains of Ig, which are 
encoded  by  genes  on  separate  chromosomes.  The  identical  problems  have 
hampered serological investigations of idiotypic inheritance in animal systems. 
In future studies, antibodies of predefined specificity against several different 
CDR and framework regions in the RF molecule may enable us to ascertain the 
individual role of light and heavy chain variable regions in the inheritance of 
IgM-RF idiotypes (8, 22-27). 
Kabat et al.  and Kin& and Capra  (28-30)  have proposed that the variable 
region genes of immunoglobulin are assembled from small  segments of DNA 
"minigenes." One experimental approach to test the minigene/gene insertion 
theory  is  to  analyze  idiotype-bearing antibodies  in  animals  suppressed  with 
antibodies against adjacent framework regions (29).  Experiments of this type 
require antiidiotype reagents that delineate relatively short primary structures 
in the variable regions of light and heavy chains. A similar experimental approach 
would help assess the role of gene conversion in immunoglobulin diversification. 
Antibodies against synthetic peptides should facilitate a  serological analysis  of 
the possible role of both gene insertion and gene conversion (31,  32)  in the 
generation of antibody diversity. The serological results could then be confirmed 
by direct protein and DNA sequence analysis. 
Summary 
Antibody against a cross-reactive idiotype (CRI) on human IgM-rheumatoid 
factor (RF) antibodies was induced by immunization of rabbits with a synthetic 
peptide (PSL2) corresponding to the second complementarity-determining re- 
gion (CDR), and adjacent amino acid residues of the kappa light chain of the 
IgM-RF Sie.  The anti-peptide antibody bound efficiently to IgM-RF proteins 
known to share a cross-reactive idiotype, and to their isolated kappa chains. The 
anti-CRI was absorbed by, and eluted from, a peptide-Sepharose affinity column. 
The antibody activity was inhibited by the free peptide in solution. The anti- 
peptide antibody thus  identifies a  public idiotype on human IgM-RF, that is 
largely dependent on the primary sequence of the second CDR of the light chain. 
Such peptide-induced antiidiotypes of predefined specificity may facilitate studies 
of the molecular basis of idiotypic cross-reactions, the inheritance and somatic 
diversifcation of antibody molecules, and the regulation of the idiotype network. 1510  SYNTHETIC  PEPTIDE-INDUCED  ANTI-CROSS-REACTIVE  IDIOTYPE 
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